Glaucoma drug NCX 470 reaches another major market as Nicox’s partner strategy pays off

NCX 470 is moving from a late-stage development asset toward a potential global commercial franchise as regulatory reviews expand across the world’s largest ophthalmology markets. Ocumension Therapeutics has submitted a New Drug Application in China for the nitric oxide-donating glaucoma treatment, adding a second major regulatory review after Kowa Company, Ltd. filed the drug in the United States in July. For Nicox SA, the milestone is particularly important because the company has structured NCX 470 around partnerships that can generate milestone payments and recurring royalties without requiring it to build large commercial organizations of its own. With Phase 3 development also underway in Japan, the next 12 to 18 months could determine whether more than a decade of investment in nitric oxide-based ophthalmology begins producing meaningful commercial returns.

The Chinese application seeks approval of NCX 470, also known as bimatoprost grenod, for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The submission relies on the same broad clinical package supporting the United States filing, including the Mont Blanc and Denali Phase 3 trials. Denali included sites in China, helping Ocumension Therapeutics satisfy local clinical requirements while avoiding the need to reproduce the full late-stage program specifically for the Chinese market.

Both pivotal studies met their primary objectives by demonstrating that once-daily NCX 470 was non-inferior to latanoprost. That replicated outcome substantially reduces one of the largest development risks surrounding the asset. Nicox SA and its partners must now persuade regulators and eventually physicians that the drug’s nitric oxide-enhanced mechanism offers enough additional pressure control to earn a place in a highly competitive market dominated by established and often inexpensive therapies.

China and United States reviews could move NCX 470 from development spending to recurring partner revenue

The China filing materially changes the financial profile of NCX 470 because Nicox SA is not responsible for building and funding a commercial operation in the territory. Ocumension Therapeutics holds rights to the medicine in China, South Korea and several Southeast Asian markets and has already paid Nicox SA approximately €18 million in licensing fees while funding half of the Denali Phase 3 trial costs.

Nicox SA is eligible to receive tiered royalties ranging from 6% to 12% on sales generated by Ocumension Therapeutics. That structure creates a potential recurring revenue stream without requiring Nicox SA to absorb the full cost of sales representatives, distribution, reimbursement negotiations and local marketing infrastructure.

Ocumension Therapeutics also has an existing ophthalmology business in China and already markets ZERVIATE, another Nicox-originated product. The established infrastructure could allow NCX 470 to move into commercial channels more efficiently if the National Medical Products Administration grants approval.

A similar strategy applies outside the Ocumension Therapeutics territories. Kowa Company, Ltd. controls development and commercialization across much of the rest of the world, including the United States. The July 2026 United States New Drug Application triggered a €3 million milestone payment to Nicox SA, while the agreement provides additional regulatory and commercial milestones as well as future royalties.

This asset-light model reduces Nicox SA’s financial exposure during the most expensive phase of drug commercialization. It also shifts much of the execution risk to its partners. Regulatory delays, slower-than-expected launches or weak prescribing would directly affect the timing and scale of royalties even if Nicox SA itself executes its contractual obligations.

The commercial opportunity is therefore increasingly tied to partner performance rather than internal sales execution. That distinction makes regulatory progress especially important because each successful filing reduces the number of steps separating Nicox SA from potential recurring revenue.

Two positive Phase 3 trials reduce clinical risk while leaving differentiation as the commercial challenge

The Denali Phase 3 trial enrolled 696 patients with open-angle glaucoma or ocular hypertension across 90 sites in China and the United States. NCX 470 0.1% was compared with latanoprost 0.005% using intraocular pressure measurements collected at six time points through the third month of treatment.

NCX 470 reduced intraocular pressure by approximately 7.9 to 10.0 millimeters of mercury from baseline compared with reductions of roughly 7.1 to 9.8 millimeters of mercury for latanoprost. The investigational treatment produced statistically greater reductions at three of the six time points and numerically greater reductions at five.

The trial met its primary non-inferiority endpoint but did not satisfy the prespecified overall secondary test for superiority. That result supports approval but complicates the commercial message. NCX 470 cannot simply be presented as a universally superior version of latanoprost based on the Phase 3 evidence.

The earlier Mont Blanc study produced a comparable pattern, with NCX 470 lowering pressure by roughly 8.0 to 9.7 millimeters of mercury and latanoprost producing reductions of around 7.1 to 9.4 millimeters of mercury. Reproducing the primary efficacy result across two pivotal trials strengthens regulatory confidence and provides physicians with a more dependable evidence base.

The next challenge is establishing why physicians should prescribe NCX 470 when multiple generic prostaglandin analogs are already available. Glaucoma treatment often continues for years, making small differences in efficacy, tolerability, convenience and cost commercially significant.

NCX 470 combines bimatoprost with a nitric oxide-donating component. Bimatoprost primarily promotes aqueous humor drainage through the uveoscleral pathway, while nitric oxide is designed to improve conventional trabecular outflow. The dual mechanism is intended to provide stronger pressure lowering in a single once-daily eye drop.

The potential advantage is relevant because intraocular pressure remains the principal modifiable risk factor for glaucoma progression. Even modest additional reductions can matter for patients who remain above their target pressure despite treatment.

Safety could influence prescribing in the opposite direction. Conjunctival hyperemia occurred in approximately 22% of NCX 470-treated patients in Denali compared with about 9.2% of patients receiving latanoprost. Treatment discontinuations were also somewhat higher with NCX 470 during the longer safety period.

The commercial profile will therefore depend on whether physicians consider the additional pressure reduction sufficient to offset greater ocular redness for selected patients.

Japan development gives NCX 470 a third route to becoming a global ophthalmology franchise

NCX 470 is not limited to the Chinese and United States regulatory strategies. Kowa Company, Ltd. is also conducting Phase 3 clinical development in Japan, creating the possibility that the same asset could eventually generate revenue across three major ophthalmology markets.

A broad geographic footprint is particularly valuable for Nicox SA because the company’s economics are based largely on milestones and royalties. Approval in one territory would begin validating the model, while approvals across several markets could diversify revenue and reduce dependence on a single launch.

Management has indicated that a United States regulatory decision could arrive around summer 2027 if the application follows a standard review timeline, with commercialization potentially beginning during the second half of that year. Chinese approvals frequently occur within roughly 12 to 18 months of filing, although the timing is not guaranteed and regulatory authorities can request additional information.

That creates the possibility of United States and Chinese regulatory decisions occurring within a relatively concentrated period. A positive outcome in both markets would substantially change Nicox SA’s position from a development-stage ophthalmology company into a business with multiple potential royalty streams tied to the same product.

Regulatory success would still represent only the beginning of the commercial test. Pricing, reimbursement, physician awareness and formulary placement will determine how rapidly NCX 470 penetrates markets already served by prostaglandin analogs, fixed combinations and other pressure-lowering therapies.

The partner structure partly reduces this risk because Kowa Company, Ltd. and Ocumension Therapeutics already possess regional commercial capabilities. Nicox SA does not need to recreate those networks, but its ultimate economics remain dependent on how effectively its partners use them.

Nicox shares remain cautious as investors wait for approvals rather than another filing

Nicox SA shares were trading around €0.39 on August 10, only modestly above the previous close near €0.38. The restrained movement indicates that investors likely viewed the Chinese application as an expected milestone rather than a major surprise after the company disclosed favorable regulatory discussions earlier in the year.

The muted response should not be interpreted as evidence that the filing lacks importance. Regulatory submissions reduce execution risk gradually, while biotechnology valuations often react more strongly to final approvals, unexpected review developments or evidence of commercial uptake. This interpretation is an inference from the share-price movement rather than a confirmed explanation from market participants.

NCX 470 is now at a stage where clinical efficacy risk is becoming less dominant and regulatory and commercialization risk are taking its place. Two Phase 3 trials have already demonstrated the pressure-lowering activity required to support applications. The largest remaining questions concern approval, product labeling, competitive positioning and the eventual size of partner-generated sales.

For Nicox SA shareholders, that transition matters. Large clinical programs consume capital, while approved partnered products can generate milestone and royalty income. Moving NCX 470 through multiple regulatory reviews therefore has the potential to change the company’s cash-flow profile even before sales reach significant scale.

The current valuation still reflects considerable uncertainty. Regulatory authorities could request additional analyses, extend their reviews or impose labeling that limits commercial differentiation. Even successful approval would not guarantee strong physician adoption against established therapies.

The opportunity is equally clear. NCX 470 now has replicated Phase 3 efficacy, filings underway in the United States and China, development progressing in Japan and commercial partners capable of reaching major ophthalmology markets. If those programs convert into approvals, Nicox SA could begin generating recurring income from a drug it does not need to commercialize directly.

Key takeaways on what the NCX 470 China filing means for Nicox SA

• Ocumension Therapeutics has submitted NCX 470 for Chinese approval in open-angle glaucoma and ocular hypertension, giving the drug active regulatory pathways in two major markets.
• Kowa Company, Ltd. filed the United States New Drug Application in July 2026, while Phase 3 development continues in Japan.
• The China filing is supported by the Mont Blanc and Denali Phase 3 trials, both of which met their primary non-inferiority endpoints against latanoprost.
• Denali showed numerically greater intraocular pressure reductions with NCX 470 at five of six measured time points, although the trial did not meet its overall superiority endpoint.
• NCX 470 combines bimatoprost with nitric oxide donation, giving the medicine two complementary mechanisms for increasing aqueous humor drainage.
• Higher conjunctival hyperemia rates could influence the product’s competitive profile even if regulators approve the treatment.
• Ocumension Therapeutics holds rights across China and several Asian territories, with Nicox SA eligible for royalties ranging from 6% to 12% on partner sales.
• Kowa Company, Ltd. controls most other global territories and has already triggered a €3 million milestone payment through the United States filing.
• Nicox SA’s partnership model limits direct commercialization costs while making future revenue dependent on regulatory decisions and partner execution.
• The modest share-price reaction suggests investors are increasingly waiting for approval decisions and commercial evidence rather than additional filing milestones.